Akira Furuta1, Tokunori Yamamoto2, Yasuyuki Suzuki3, Momokazu Gotoh2, Shin Egawa4, Naoki Yoshimura5. 1. Department of Urology, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan. a-furuta@rf7.so-net.ne.jp. 2. Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 3. Department of Urology, Tokyo Metropolitan Rehabilitation Hospital, Tokyo, Japan. 4. Department of Urology, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan. 5. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
INTRODUCTION AND HYPOTHESIS: Chronic inflammatory conditions seem to be a shared characteristic in patients with interstitial cystitis (IC) and overactive bladder (OAB). Thus, we measured 40 inflammatory urine markers in IC patients with or without Hunner's lesions (HIC and NHIC respectively) and OAB patients. METHODS: Urine was collected from consecutive HIC patients, NHIC patients, and age and gender-matched OAB patients with no history of IC, recurrent urinary tract infection or bladder cancer. The diagnosis of IC was based on the Asian IC guideline criteria. A representative 40 inflammatory growth factors, cytokines, and chemokines in urine were measured using a MILLIPLEX immunoassay kit. Statistical differences in these markers among the groups were determined by nonparametric ANOVA followed by multiple comparison test. The diagnostic efficiency of these markers was measured using receiver operating characteristic analysis. RESULTS: Vascular endothelial growth factor (VEGF), interleukin-1α (IL-1α), IL-6, and chemokines including CCL2, CCL5, CXCL1, CXCL8, and CXCL10 were significantly increased in HIC (n = 30) and NHIC (n = 30) patients compared with OAB (n = 28) patients. The significant increases in CXCL8 and CXCL10 were also found in HIC patients compared with NHIC patients. However, there were no significant differences in the other urine markers among the groups. Area under the curves for VEGF, CXCL10, CXCL8, IL-1α, CCL5, CCL2, IL-6, and CXCL1 to detect IC in these patients were 0.87, 0.86, 0.81, 0.80, 0.80, 0.71, 0.66, and 0.50 respectively. CONCLUSIONS: The increases in angiogenesis-associated proteins such as VEGF and CXCL10 may be pathophysiologically important for the development of IC.
INTRODUCTION AND HYPOTHESIS: Chronic inflammatory conditions seem to be a shared characteristic in patients with interstitial cystitis (IC) and overactive bladder (OAB). Thus, we measured 40 inflammatory urine markers in IC patients with or without Hunner's lesions (HIC and NHIC respectively) and OABpatients. METHODS: Urine was collected from consecutive HIC patients, NHIC patients, and age and gender-matched OABpatients with no history of IC, recurrent urinary tract infection or bladder cancer. The diagnosis of IC was based on the Asian IC guideline criteria. A representative 40 inflammatory growth factors, cytokines, and chemokines in urine were measured using a MILLIPLEX immunoassay kit. Statistical differences in these markers among the groups were determined by nonparametric ANOVA followed by multiple comparison test. The diagnostic efficiency of these markers was measured using receiver operating characteristic analysis. RESULTS:Vascular endothelial growth factor (VEGF), interleukin-1α (IL-1α), IL-6, and chemokines including CCL2, CCL5, CXCL1, CXCL8, and CXCL10 were significantly increased in HIC (n = 30) and NHIC (n = 30) patients compared with OAB (n = 28) patients. The significant increases in CXCL8 and CXCL10 were also found in HIC patients compared with NHIC patients. However, there were no significant differences in the other urine markers among the groups. Area under the curves for VEGF, CXCL10, CXCL8, IL-1α, CCL5, CCL2, IL-6, and CXCL1 to detect IC in these patients were 0.87, 0.86, 0.81, 0.80, 0.80, 0.71, 0.66, and 0.50 respectively. CONCLUSIONS: The increases in angiogenesis-associated proteins such as VEGF and CXCL10 may be pathophysiologically important for the development of IC.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Alaina J Ammit; Aili L Lazaar; Carla Irani; Geraldine M O'Neill; Nancy D Gordon; Yassine Amrani; Raymond B Penn; Reynold A Panettieri Journal: Am J Respir Cell Mol Biol Date: 2002-04 Impact factor: 6.914
Authors: Deborah R Erickson; Sharon X Xie; Veer P Bhavanandan; Marcia A Wheeler; Robert E Hurst; Lawrence M Demers; Leslie Kushner; Susan K Keay Journal: J Urol Date: 2002-06 Impact factor: 7.450
Authors: Joop P van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul Irwin; Svend Mortensen; Arndt van Ophoven; John L Osborne; Ralph Peeker; Benedikte Richter; Claus Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele Journal: Eur Urol Date: 2007-09-20 Impact factor: 20.096
Authors: Michael Guo; Phat Chang; Eric Hauke; Beatrice M Girard; Katharine Tooke; Jacqueline Ojala; Susan M Malley; Harrison Hsiang; Margaret A Vizzard Journal: Front Syst Neurosci Date: 2018-04-06
Authors: Lauren K L Drage; Wendy Robson; Catherine Mowbray; Ased Ali; John D Perry; Katherine E Walton; Christopher Harding; Robert Pickard; Judith Hall; Phillip D Aldridge Journal: Immun Ageing Date: 2019-07-11 Impact factor: 6.400
Authors: Roopali Roy; Alisa J Stephens; Cassandra Daisy; Lauren Merritt; Craig W Newcomb; Jiang Yang; Adelle Dagher; Adam Curatolo; Monisha Sachdev; Brendan McNeish; Richard Landis; Adrie van Bokhoven; Andrew El-Hayek; John Froehlich; Michel A Pontari; David Zurakowski; Richard S Lee; Marsha A Moses Journal: J Urol Date: 2020-10-07 Impact factor: 7.450